Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Dokumenttyp:
Zeitschriftenaufsatz
Autor(en):
Thaçi, D.; Pinter, A.; Sebastian, M.; Termeer, C.; Sticherling, M.; Gerdes, S.; Wegner, S.; Krampe, S.; Bartz, H.; Rausch, C.; Mensch, A.; Eyerich, K.
Login
BibTeX